A China- and U
A China- and U.S.-operating biopharmaceutical company developing innovative CAR T-cell therapies for hematologic malignancies and solid tumors. Its integrated cell-therapy capabilities span target discovery, antibody development, clinical trials, and commercial-scale manufacturing, with autologous, allogeneic, and in vivo CAR-T programs.